Form 4 for KURA Kura Oncology, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0000950170-24-001850 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-04 | 2024-01-02 | KURA | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +21.2K | 50.4K | +73% | $0 |
| D | 2024-01-04 | 2024-01-02 | KURA | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +42.5K | 42.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | A | A | 21,250 | $0.00 | 50,411 | D | — | — | (F1) Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28. (F2) Includes 1,489 shares acquired on May 17, 2023 and 206 shares acquired on November 17, 2023 pursuant to the Issuer's Employee Stock Purchase Plan. |
| 2 | Derivative | Option to purchase common stock | 2024-01-02 | A | A | 42,500 | $0.00 | 42,500 | D | $15.36 · — to 2034-01-01 | 42,500 Common Stock | (F3) This option vests in 48 equal monthly installments commencing on the grant date. |